Literature DB >> 8826861

Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases.

A Platz1, P Sevigny, T Norberg, P Ring, B Lagerlöf, U Ringborg.   

Abstract

A common characteristic of cancer cells is unrestrained cell division. This may be caused by mutational changes in genes coding for components of cell cycle-controlling networks. Alterations in genes involved in G1 checkpoint control have been registered in many human tumours, and investigations from several laboratories show that such alterations, taken together, are the most frequent changes detected in cancer cells. The present paper describes mutational analysis by polymerase chain reaction-single-strand conformation polymorphism (PCR/SSCP) and nucleotide sequence analysis of the genes coding for the p15, p53 and N-ras proteins in 26 metastases from 25 melanoma patients. The registered mutation frequencies add together with previously registered mutations in p16 in the same patient samples to a substantial total frequency of 44% of patients with mutation in at least one of the investigated genes. These results show the occurrence of heterogeneous defects among components of the cell cycle controlling machinery in a human melanoma tumour sample collection and demonstrate that the total frequency of detected alterations increases with the number of cell cycle controlling genes included in the screening panel.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826861      PMCID: PMC2074743          DOI: 10.1038/bjc.1996.460

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  39 in total

1.  WAF1, a potential mediator of p53 tumor suppression.

Authors:  W S el-Deiry; T Tokino; V E Velculescu; D B Levy; R Parsons; J M Trent; D Lin; W E Mercer; K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1993-11-19       Impact factor: 41.582

2.  Manifold sequencing: efficient processing of large sets of sequencing reactions.

Authors:  A Lagerkvist; J Stewart; M Lagerström-Fermér; U Landegren
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

3.  Lack of allelic deletion and point mutation as mechanisms of p53 activation in human malignant melanoma.

Authors:  J S Castresana; M P Rubio; J J Vázquez; M Idoate; A J Sober; B R Seizinger; R L Barnhill
Journal:  Int J Cancer       Date:  1993-10-21       Impact factor: 7.396

4.  Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung.

Authors:  Y Kishimoto; Y Murakami; M Shiraishi; K Hayashi; T Sekiya
Journal:  Cancer Res       Date:  1992-09-01       Impact factor: 12.701

5.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.

Authors:  M Serrano; G J Hannon; D Beach
Journal:  Nature       Date:  1993-12-16       Impact factor: 49.962

6.  Ras mutations in human melanoma: a marker of malignant progression.

Authors:  N J Ball; J J Yohn; J G Morelli; D A Norris; L E Golitz; J P Hoeffler
Journal:  J Invest Dermatol       Date:  1994-03       Impact factor: 8.551

7.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22.

Authors:  L A Cannon-Albright; D E Goldgar; L J Meyer; C M Lewis; D E Anderson; J W Fountain; M E Hegi; R W Wiseman; E M Petty; A E Bale
Journal:  Science       Date:  1992-11-13       Impact factor: 47.728

8.  Linkage of cutaneous malignant melanoma/dysplastic nevi to chromosome 9p, and evidence for genetic heterogeneity.

Authors:  A M Goldstein; N C Dracopoli; M Engelstein; M C Fraser; W H Clark; M A Tucker
Journal:  Am J Hum Genet       Date:  1994-03       Impact factor: 11.025

9.  TP53 allele loss, mutations and expression in malignant melanoma.

Authors:  V A Flørenes; T Oyjord; R Holm; M Skrede; A L Børresen; J M Nesland; O Fodstad
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

10.  Detection of p53 gene mutations in human ovarian and endometrial cancers by polymerase chain reaction-single strand conformation polymorphism analysis.

Authors:  M Naito; M Satake; E Sakai; Y Hirano; N Tsuchida; H Kanzaki; Y Ito; T Mori
Journal:  Jpn J Cancer Res       Date:  1992-10
View more
  5 in total

1.  Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.

Authors:  K Laud; C Marian; M F Avril; M Barrois; A Chompret; A M Goldstein; M A Tucker; P A Clark; G Peters; V Chaudru; F Demenais; A Spatz; M W Smith; G M Lenoir; B Bressac-de Paillerets
Journal:  J Med Genet       Date:  2005-06-03       Impact factor: 6.318

2.  Novel insights into the pathogenesis and treatment of NRAS mutant melanoma.

Authors:  Jeffrey Zhao; Carlos Galvez; Kathryn Eby Beckermann; Douglas B Johnson; Jeffrey A Sosman
Journal:  Expert Rev Precis Med Drug Dev       Date:  2021-08-11

3.  Amino acids and mTOR mediate distinct metabolic checkpoints in mammalian G1 cell cycle.

Authors:  Mahesh Saqcena; Deepak Menon; Deven Patel; Suman Mukhopadhyay; Victor Chow; David A Foster
Journal:  PLoS One       Date:  2013-08-19       Impact factor: 3.240

4.  Non-destructive, label free identification of cell cycle phase in cancer cells by multispectral microscopy of autofluorescence.

Authors:  Jared M Campbell; Abbas Habibalahi; Saabah Mahbub; Martin Gosnell; Ayad G Anwer; Sharon Paton; Stan Gronthos; Ewa Goldys
Journal:  BMC Cancer       Date:  2019-12-21       Impact factor: 4.430

5.  CDKN2A Polymorphism in Melanoma Patients in Colombian Population: A Case-Control Study.

Authors:  Jose D Tovar-Parra; Luz D Gutiérrez-Castañeda; Sebastián R Gil-Quiñones; Jhon A Nova; Leonardo Pulido
Journal:  Biomed Res Int       Date:  2020-10-10       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.